Literature DB >> 24530473

Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?

Anthony J Mutsaers1, Carl R Walkley2.   

Abstract

Osteosarcoma is a disease with many complex genetic abnormalities but few well defined genetic drivers of tumor initiation and evolution. The disease is diagnosed and defined through the observation of malignant osteoblastic cells that produce osteoid, however the exact cell of origin for this cancer remains to be definitively defined. Evidence exists to support a mesenchymal stem cell as well as committed osteoblast precursors as the cell of origin. Increasing numbers of experimental models have begun to shed light on to the likely cell population that gives rise to OS in vivo with the weight of evidence favoring an osteoblastic population as the cell of origin. As more information is gathered regarding osteosarcoma initiating cells and how they may relate to the cell of origin we will derive a better understanding of the development of this disease which may ultimately lead to clinical improvements through more personalized therapeutic approaches.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mesenchymal stem cell; Osteoblast; Osteosarcoma; Tumor initiating cell; p53

Mesh:

Year:  2014        PMID: 24530473     DOI: 10.1016/j.bone.2014.02.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  68 in total

Review 1.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

Review 2.  Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.

Authors:  Jonathan A R Gordon; Martin A Montecino; Rami I Aqeilan; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

3.  Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.

Authors:  Rui Yang; Sajida Piperdi; Yue Zhang; Zhu Zhu; Neophytos Neophytou; Bang H Hoang; Gary Mason; David Geller; Howard Dorfman; Paul A Meyers; John H Healey; Donald G Phinney; Richard Gorlick
Journal:  Clin Orthop Relat Res       Date:  2016-01       Impact factor: 4.176

4.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

Review 5.  Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma.

Authors:  Qing-Hong Su; Xiao-Qun Xu; Jun-Fu Wang; Jun-Wen Luan; Xia Ren; Hai-Yan Huang; Si-Shan Bian
Journal:  Chin J Integr Med       Date:  2019-06-04       Impact factor: 1.978

6.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.

Authors:  Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2020-02-14       Impact factor: 6.389

7.  WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma.

Authors:  Sara Del Mare; Hussam Husanie; Ortal Iancu; Mohammad Abu-Odeh; Konstantinos Evangelou; Francesca Lovat; Stefano Volinia; Jonathan Gordon; Gail Amir; Janet Stein; Gary S Stein; Carlo M Croce; Vassilis Gorgoulis; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2016-08-22       Impact factor: 12.701

8.  Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status.

Authors:  Jeremy M Rosenblum; N Ari Wijetunga; Melissa J Fazzari; Mark Krailo; Donald A Barkauskas; Richard Gorlick; John M Greally
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

9.  Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.

Authors:  Eric R Molina; Letitia K Chim; Maria C Salazar; Shail M Mehta; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Tejus Satish; Sana Mohiuddin; David McCall; Ana Maria Zaske; Branko Cuglievan; Alexander J Lazar; David W Scott; Jane K Grande-Allen; Joseph A Ludwig; Antonios G Mikos
Journal:  Acta Biomater       Date:  2019-09-19       Impact factor: 8.947

Review 10.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.